Trevi Therapeutics Announces Results From Phase 2b/3 PRISM Open-Label Extension Study Of Haduvio In Prurigo Nodularis
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics, Inc. (NASDAQ:TRVI) has announced the 52-week results from its phase 2b/3 PRISM open-label extension study of Haduvio for the treatment of prurigo nodularis. The data shows continued reduction in itch over 52 weeks for the participants who remained in the study. The safety data were generally consistent with the safety profile of Haduvio observed in the 14-week portion of PRISM and previous trials of Haduvio.
October 13, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevi Therapeutics' Haduvio shows positive results in a 52-week phase 2b/3 PRISM study for prurigo nodularis. This could potentially lead to regulatory approval and market expansion.
The positive results from the 52-week PRISM study of Haduvio indicate that the drug is effective and safe for long-term use. This could potentially lead to regulatory approval and market expansion, which would positively impact Trevi Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100